(Q44885385)

English

Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

based on heuristic

inferred from title

1

object named as

Peter R Joyce

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

2

object named as

Roger T Mulder

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

4

object named as

Suzanne E Luty

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

C. Robert Cloninger

5

object named as

C Robert Cloninger

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

3

object named as

Janice M McKenzie

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

180-186

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

A psychobiological model of temperament and character

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

21 January 2018

The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

21 January 2018

The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

21 January 2018

Assessment of social adjustment by patient self-report

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

21 January 2018

Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

21 January 2018

Can mildly depressed outpatients with atypical depression benefit from antidepressants?

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

21 January 2018

Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

21 January 2018

Forms of atypical depression and their response to antidepressant drugs.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

Borderline personality disorder in major depression: symptomatology, temperament, character, differential drug response, and 6-month outcome

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

The validity of atypical depression in DSM-IV.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

A Placebo-Controlled Study of Fluoxetine Versus Imipramine in the Acute Treatment of Atypical Depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluoxetine versus phenelzine in atypical depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

Depressive Classification and Prediction of Response to Phenelzine

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

Nosology of atypical depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of iproniazid in depressive syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20001

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.20001

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44885385&oldid=2055158338"